Abruzzo, Lynne

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia

Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 584

BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 484

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Burger, J. A., Landau, D. A., Taylor-Weiner, A., Bozic, I., Zhang, H., Sarosiek, K., Wang, L., Stewart, C., Fan, J., Hoellenriegel, J., et al. (2016) · Nature Communications

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 345